Clinical evaluation of extra-hematologic comorbidity in myelodysplastic syndromes: ready-to-wear versus made-to-measure tool

Registros relacionados

• Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome
  por: Matteo G. Della Porta, et al.
  Publicado em: (2011-03-01)
• Clinical relevance of extra-hematologic comorbidity in the management of patients with myelodysplastic syndrome
  por: Matteo Giovanni Della Porta, et al.
  Publicado em: (2009-05-01)
• Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)
  por: Luca Malcovati, et al.
  Publicado em: (2011-10-01)
• Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1
  por: Ilaria Ambaglio, et al.
  Publicado em: (2013-03-01)
• Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
  por: Malcovati, L, et al.
  Publicado em: (2011)